by E4H | Jan 9, 2023 | Insights
Expanded access programs (EAPs) are growing in popularity throughout North America and Europe. This leaves vast untapped opportunities to provide and establish pharmaceutical supplier relationships in the rest of the world. While the primary goal of an EAP is to bring...
by E4H | Jan 9, 2023 | Insights
For many biopharma companies, running an expanded access program (EAP or Compassionate Use Program, CUP) is an extremely important component of bringing early treatment options to patients with high unmet medical needs, yet it is understood that offering expanded...
by E4H | Jan 9, 2023 | News
AKANTIOR® is slated to become the first approved orphan medicinal product for acanthamoeba keratitis after more than 15 years of eye disease research conducted by SIFI Durbin has been appointed to design and implement an Early Access Program within Germany,...
by E4H | Jan 6, 2023 | Insights
Imagine you have a new, exciting therapy recently approved in one market. It’s going to save lives, inspire further innovations, and perhaps even shape the future of healthcare. It requires specialist treatment that is only available through certain approved and...
